Super Current Affairs

Science & Tech

Drug-resistant tuberculosis: IISc tests isoniazid-vancomycin combination in clinical isolates and mice

17 November 20263 min1 source4 questionsStory 13 of 13

Source:The HinduThe Hindu

Subject: Science and Technology (Health biotechnology, infectious diseases) and Social Sector (Health)

Key points for Prelims: Isoniazid, Vancomycin, Mycobacterium tuberculosis, Multidrug-resistant (MDR) TB, Indian Institute of Science, National Tuberculosis Institute

Mains syllabus mapping

  • General Studies Paper 2: Health: diseases, government initiatives and institutions related to health
  • General Studies Paper 3: Science and technology: developments and their applications in health and biotechnology; antimicrobial resistance

Key facts for one-day exams

  • Mycobacterium tuberculosis causes tuberculosis.
  • Isoniazid and vancomycin were the two drugs combined in the study.
  • Most clinical isolates showed over 90% lower bacterial growth with combination treatment.
  • The mouse experiment assessed bacterial load after 10 days of treatment.
  • The study was published in Microbiology Spectrum.

IISc isoniazid-vancomycin combination for drug-resistant TB: why in the news?

The study published in Microbiology Spectrum reports a laboratory and mouse-model finding that combining isoniazid with vancomycin can reverse resistance in drug-resistant tuberculosis isolates, offering a potential new treatment strategy for a persistent global health challenge.

Researchers at the Indian Institute of Science (IISc) have identified a strategy to restore the effectiveness of isoniazid, a frontline drug for tuberculosis, by combining it with the antibiotic vancomycin. The study, published in Microbiology Spectrum, tested the combination against clinical isolates of Mycobacterium tuberculosis obtained from patient sputum samples in collaboration with the National Tuberculosis Institute, Bengaluru, and in a mouse model infected with multidrug-resistant (MDR) M. tuberculosis.

According to IISc, isoniazid is a prodrug that requires activation by a bacterial enzyme, but mutations in specific genes can create resistant bacteria that block this pathway. Vancomycin, on the other hand, has difficulty penetrating the impermeable cell wall of M. tuberculosis. When used together, a loss of cell wall integrity allows vancomycin to enter the cell and start killing the bacteria. Most of the clinical isolates showed more than 90% reduction in bacterial growth under the combination treatment, including isolates resistant to isoniazid as well as MDR isolates.

In the mouse model, after 10 days of treatment, neither isoniazid nor vancomycin alone produced a significant reduction in bacterial burden. However, the combination resulted in an approximately 10-fold reduction in bacterial load both in the lungs and spleen. Histopathological examination also revealed that the combination treatment lowered the number of lung granulomas. The team is currently working to advance this combination for clinical trials.

What is the history of isoniazid in TB treatment?

Isoniazid was first synthesised in 1912. Isoniazid is on the World Health Organization Model List of Essential Medicines. Multidrug-resistant TB is defined as resistance to at least isoniazid and rifampicin.

Why does isoniazid resistance occur?

Isoniazid is a prodrug that must be activated by a bacterial enzyme to be effective. Mutations in specific genes can create resistant bacteria that block this activation pathway, allowing Mycobacterium tuberculosis to survive despite exposure to the drug.

How does the combination work?

Vancomycin normally has difficulty penetrating the impermeable cell wall of M. tuberculosis. When used together with isoniazid, a loss of cell wall integrity allows vancomycin to enter the cell and start killing the bacteria. The combination substantially reduced bacterial burden compared with either drug alone, with most tested isolates showing more than 90% lower growth, including isoniazid-resistant and MDR isolates.

What is the next step?

The team is currently working to advance the combination for clinical trials. The findings from laboratory isolates and a mouse model are encouraging but should not be equated with demonstrated effectiveness or safety in human patients.

Tuberculosis drug tests in the mouse model

TreatmentBacterial load after 10 days
Isoniazid aloneNo significant reduction
Vancomycin aloneNo significant reduction
CombinationApproximately tenfold reduction

Key terms

Tuberculosis:
Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis.
Prodrug:
A prodrug is a substance that must be converted into an active form to produce its intended drug effect.
Drug resistance:
Drug resistance is the ability of a microorganism to survive or grow despite exposure to a drug intended to inhibit or kill it.
Clinical isolate:
A clinical isolate is a microorganism obtained from a patient sample for study or testing.

IISc isoniazid-vancomycin combination for drug-resistant TB: why it matters for exams

Syllabus: Science and Technology: Biotechnology and antimicrobial resistance; Society: Public health and communicable diseases

Common mistake: Examiners may present the mouse-model results as successful human clinical-trial results; the team is working to advance the combination towards clinical trials.

Mains practice questions

Question 1(GS-3 | 250 words | 15 marks)

Drug-resistant tuberculosis poses a serious challenge to India's public health goals. Critically examine the role of research institutions like the Indian Institute of Science in developing combination drug strategies to counter antimicrobial resistance, and discuss the challenges in translating such laboratory findings into clinical practice.

Answer outline

  • Introduction: Open by noting that drug-resistant TB, especially MDR-TB, weakens frontline drugs such as isoniazid, and that the IISc study shows a combination can restore their effect in laboratory and mouse-model settings.
  • Body:
    • Explain the mechanism: isoniazid needs bacterial activation and resistance mutations block this, while vancomycin struggles to enter the impermeable cell wall, and the combination weakens that wall so both work together.
    • Highlight the evidence: over 90% growth reduction in most clinical isolates, and about 10-fold lower bacterial load in mouse lungs and spleen where single drugs failed.
    • Role of research institutions and collaboration: IISc working with the National Tuberculosis Institute, Bengaluru, linking basic biochemistry with clinical samples and national TB institutions.
    • Challenges in translation: laboratory and animal results do not guarantee human efficacy, toxicity and dosing of vancomycin, which is an intravenous drug, need trials, and clinical trial approval and funding are required.
    • Broader policy angle: need for stronger drug discovery pipelines, surveillance of resistance and integration with national TB programmes to avoid repeating the cycle of resistance.
  • Conclusion: A balanced way forward combines promising research with rigorous clinical trials, stewardship of existing antibiotics and sustained support to research institutions so that laboratory breakthroughs can reach patients under the national TB elimination goals.

Stuck? Get it in one tap

Practice questions

Pick an answer, then read the explanation.

  1. Q1Easy

    Which institution’s Department of Biochemistry studied the isoniazid-vancomycin combination against drug-resistant tuberculosis?

  2. Q2Hard

    Consider the following statements about the isoniazid-vancomycin study:

    1. 1.Isoniazid requires activation by a bacterial enzyme.
    2. 2.Vancomycin readily penetrates the impermeable cell wall of Mycobacterium tuberculosis when used alone.
    3. 3.The combination was tested against clinical isolates obtained from sputum samples.

    Which of the statements given above are correct?

  3. Q3Medium

    After 10 days of combination treatment, approximately how much did bacterial load decline in the lungs and spleen of mice infected with multidrug-resistant tuberculosis?

  4. Q4Medium

    What is the research objective of combining isoniazid with vancomycin against drug-resistant tuberculosis?

Frequently asked questions

1. Which drugs did IISc researchers combine against resistant tuberculosis?

The researchers combined isoniazid and vancomycin.

2. What result did the tuberculosis drug combination show in clinical isolates?

Most isolates showed more than 90% reduction in bacterial growth, including isoniazid-resistant and multidrug-resistant isolates.

3. Has the IISc tuberculosis combination completed clinical trials?

The research team is working to advance the combination towards clinical trials. The reported tests used clinical isolates and a mouse model.

4. Why can Mycobacterium tuberculosis become resistant to isoniazid?

Mutations in specific genes can block the bacterial activation pathway needed for isoniazid to work.

All sources

Stories from the last 30 days on the same topic, state or exams

Health & EducationUPSC: Important

6 Indian institutes in QS Asia top 100, IIT Delhi leads at 66th

  • India's Rank in Representation: 2nd (after China) with 325 universities
  • Indian Institutes in Top 200: 21 (up from 20 last year)
New updateBackground GK: QS World University RankingsNodal: Ministry of EducationDon't make this mistake!
4 questions · 2 minHindustan
Science & TechUPSC: Important

Jio, OneWeb, Starlink get satcom licences in India

  • Nodal ministry: Ministry of Communications (Department of Telecommunications)
  • Steps remaining for commercial launch: Spectrum allocation and pricing; security compliance
New updateBackground GK: Satellite Communication (SATCOM)Nodal: Department of TelecommunicationsDon't make this mistake!
4 questions · 2 minHindustanDainik Bhaskar